# Compliance Report as per Regulation 27(2) of Listing Regulations, 2015

- 1. Name of the Listed Entity: BAFNA PHARMACEUTICALS LIMITED
- 2. Quarter ending: 31 MARCH 2017

## I. Composition of Board of Directors

Title (Mr. / Ms)	Name of the Director	DIN	PAN	Category (Chairperson/ Executive/Non- executive /Independent/N ominee)	Date of Appointm ent in the current term		Directorship in listed entities including this listed entity (As per Regulation 25(1) of Listing Regulations)	Committee(s) including this listed entity (As per Regulation 26(1) of Listing	No of post of Chairperson in Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
Mr.	BAFNA MAHAVEER CHAND	01458211	AACPB6411G	Chairperson/ Executive Director	01-Oct-15		0	2	1
Mr.	PARAS BAFNA	01933663	AASPB2717M	Executive Director	01-Oct-15		0	0	0
Mr.	V RAJAMANI	00052868	AAAPR3945H	Non-Executive - Independent Director	10-Sep-14	09-Sep-19	2	2	1
Ms.	R DWARAKANATHAN	01933653	ACQPD7074D	Non-Executive - Independent Director	10-Sep-14	09-Sep-19	1	2	1
Mr.	B KAMLESH KUMAR	01218959	AADPK2196G	Non-Executive - Independent Director	10-Sep-14	09-Sep-19	1	1	0
Mr.	SUNIL BAFNA	01458225	AHLPB3511D	Non-Executive - Independent Director	10-Sep-14	09-Sep-19	1	1	0
Ms.	K SABITHA	02643259	APFPS3089F	Executive Director	27-Mar-15		1	0	0

# II. Composition of Committees

Name of Committee	Name of Committee	Committee Category	
	members		Member
1. Audit Committee	V Rajamani	Non-Executive - Independent Director	Chairman
	R Dwarakanathan	Non-Executive - Independent Director	Member
	B Kamlesh Kumar	Non-Executive - Independent Director	Member
	Bafna Mahaveerchand	Executive/Managing Director	Member
2. Nomination & Remuneration Committee	R Dwarakanathan	Non-Executive - Independent Director	Chairman
	Sunil Bafna	Non-Executive - Independent Director	Member
	V Rajamani	Non-Executive - Independent Director	Member
3. Stakeholders Relationship Committee	Sunil Bafna	Non-Executive - Independent Director	Chairman
	Paras Bafna	Executive/Whole-time Director	Member
	Bafna Mahaveerchand	Executive/Managing Director	Member

III. Meeting of Board of Directors

1 ,,	, ,	Maximum gap between any two consecutive meetings (in number of days)
11-Nov-16	04-Jan-17	53
	07-Jan-17	2
	04-Feb-17	27
	14-Mar-17	37

IV. Meeting of Committees

eeting of Committees				
Name of the Committee	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings( in number of days)
Audit Committee	04-Feb-17	Yes, 3	11-Nov-16	84
Nomination & Remuneration Committee	-	-	-	-
Stakeholders Relationship Committee	-	-	-	-
Other Committee	18-Mar-17	Yes, 3	-	-

V. Related Party Transactions

Subject	Compliance status (Yes/No/NA)
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	NA
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	NA

#### VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015 Yes
- 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
- a. Audit Committee Yes
- b. Nomination & remuneration committee Yes c. Stakeholders relationship committee Yes
- d. Risk management committee NA
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements)Regulations, 2015. Yes
- 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015. Yes

for BAFNA PHARMACEUTICALS LIMITED

Date: 15-04-2017

Place: Chennai MANAGING DIRECTOR

### ANNEXURE II Format to be submitted by listed entity at the end of the financial year 31 March 2017

I. Disclosure on website in terms of Listing Regulations					
Item	Compliance status (Yes/No/NA)	If status is "No"details of non- compliance may be given here	Web address		
Details of business		Yes			
Terms and conditions of appointment of independent directors		Yes			
Composition of various committees of board of directors		Yes			
Code of conduct of board of directors and senior management personnel		Yes			
Details of establishment of vigil mechanism/ Whistle Blower policy		Yes			
Criteria of making payments to non-executive directors		Yes			
Policy on dealing with related party transactions		Yes			
Policy for determining 'material' subsidiaries		Yes			
Details of familiarization programmes imparted to independent directors		Yes			
Contact information of the designated officials of the listed entity who are respon	sible for assisting and	Yes			
handling investor grievances			1		
email address for grievance redressal and other relevant details		Yes			
Financial results		Yes			
Shareholding pattern		Yes			
Details of agreements entered into with the media companies and/or their associ	iates	NA			
New name and the old name of the listed entity		NA			
II Annual Affirmations					
Particulars					
Particulars	Regulation Number	Compliance status	If status is		
		<sub>(Yes/No/NA)</sub> refer note	"No"details of non-		
		below	compliance may be		
			given here		
to decrease discrete (a) house have a constituted in bounce of constitute (i.e., i.e., i.e., i.e., i.e., i.e.,	4.0(4)(b) 0. 35(0)	W			
Independent director(s) have been appointed in terms of specified criteria of Board composition	16(1)(b) & 25(6) 17(1)	Yes Yes	1		
Board composition  Meeting of Board of directors	17(1)	Yes	1		
Review of Compliance Reports	17(3)	Yes			
Plans for orderly succession for appointments	17(4)	Yes			
Code of Conduct	17(5)	Yes	1		
Fees/compensation	17(6)	Yes	1		
Minimum Information	17(7)	Yes			
Compliance Certificate	17(8)	Yes			
Risk Assessment & Management	17(9)	Yes			
Performance Evaluation of Independent Directors	17(10)	Yes			
Composition of Audit Committee	18(1)	Yes			
Meeting of Audit Committee	18(2)	Yes			
Composition of nomination & remuneration committee	19(1) & (2)	Yes			
Composition of Stakeholder Relationship Committee	20(1) & (2)	Yes			
Composition and role of risk management committee	21(1),(2),(3),(4)	NA			
Vigil Mechanism	22	Yes			
Policy for related party Transaction	23(1),(5),(6),(7) & (8)	Yes			
Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	NA			
Approval for material related party transactions	23(4)	Yes			
Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes			
Other Corporate Governance requirements with respect to subsidiary of listed	24(2),(3),(4),(5) & (6)	Yes	1		
entity					
Maximum Directorship & Tenure	25(1) & (2)	Yes			
Meeting of independent directors	25(3) & (4)	Yes			
Familiarization of independent directors	25(7)	Yes			
Memberships in Committees	26(1)	Yes			
Affirmation with compliance to code of conduct from members of Board of	26(3)	Yes	1		
Directors and Senior management personnel					
Disclosure of Shareholding by Non- Executive Directors	26(4)	Yes			
Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes			
III Affirmations:	•	*		*	

The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied. - Yes

for BAFNA PHARMACEUTICALS LIMITED

Mahaveerchand Bafna Managing Director